MARKET

PIRS

PIRS

Pieris Pharmaceu
NASDAQ
16.33
-0.03
-0.18%
After Hours: 16.50 +0.17 +1.04% 18:43 12/06 EST
OPEN
16.61
PREV CLOSE
16.36
HIGH
16.61
LOW
16.31
VOLUME
2.01K
TURNOVER
--
52 WEEK HIGH
22.32
52 WEEK LOW
6.20
MARKET CAP
21.56M
P/E (TTM)
-1.2949
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at PIRS last week (1125-1129)?
Weekly Report · 6d ago
Weekly Report: what happened at PIRS last week (1118-1122)?
Weekly Report · 11/25 09:54
PIERIS PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Pieris Pharmaceuticals, Inc. - PIRS
Barchart · 11/20 16:29
Weekly Report: what happened at PIRS last week (1111-1115)?
Weekly Report · 11/18 09:52
Pieris Pharmaceuticals: Q3 Earnings Snapshot
Barchart · 11/13 15:53
Weekly Report: what happened at PIRS last week (1104-1108)?
Weekly Report · 11/11 09:57
Pieris Pharmaceuticals announces first patient dosed in SELVA Phase 3 trial
TipRanks · 11/07 13:53
PALVELLA THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN SELVA PHASE 3 CLINICAL TRIAL OF QTORIN™ 3.9% RAPAMYCIN ANHYDROUS GEL (QTORIN™ RAPAMYCIN) FOR THE TREATMENT OF MICROCYSTIC LYMPHATIC MALFORMATIONS
Reuters · 11/07 13:30
More
About PIRS
Pieris Pharmaceuticals, Inc. is a biotechnology company, which discovers and develops Anticalin-based drugs to target validated disease pathways. The Company’s clinical pipeline consists of immuno-oncology (IO), bispecific in partnership with collaborators, including S095012 (also referred to as PRS-344) targeting PD-L1 and 4-1BB, SGN-BB228 (also referred to as PRS-346) targeting CD228 and 4-1BB, and BOS-342 (also referred to as PRS-342) targeting GPC3 and 4-1BB. Its Anticalin platform technology focuses on low molecular-weight Anticalin proteins that can bind tightly and specifically to a diverse range of targets. The Anticalin technology is modular, which allows it to design multimeric Anticalin based bi- and multi- specific proteins to bind with specificity to two or more targets at the same time. S095012 consists of a PD-L1-targeting antibody and 4-1BB-targeting Anticalin proteins genetically fused to each arm of the C-terminal heavy chain of the antibody.

Webull offers Pieris Pharmaceuticals Inc stock information, including NASDAQ: PIRS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PIRS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PIRS stock methods without spending real money on the virtual paper trading platform.